ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to trastuzumab, and therefore, the analysis confirms the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.

APHINITY was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.

The APHINITY trial was supported by F. Hoffmann-La Roche Ltd/Genentech and was designed by the Breast International Group (BIG) in collaboration with the sponsor.

The database was maintained at the Institut Jules Bordet Clinical Trials Support Unit (Brussels, Belgium), and the statistical analyses were carried out by Frontier Science Scotland.


Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial


E. de Azambuja; E. Agostinetto; M. Procter; D. Eiger; N. Pondé; S. Guillaume; D. Parlier; M. Lambertini; A. Desmet; C. Caballero; C. Aguila; G. Jerusalem; J.M. Walshe; E. Frank; J. Bines; S. Loibl; M. Piccart-Gebhart; M.S. Ewer; S. Dent; C. Plummer; T. Suter; on behalf of the APHINITY Steering Committee and Investigators

Publication Reference

ESMO Open | Volume 8 | Issue 1 | 100772 | February 2023